LYEL:NASDAQ, Lyell Immunopharma, Inc.
LYEL stock overview
Lyell Immunopharma, Inc. (LYEL:NASDAQ) closed at $10.88 on November 2, 2026,
down 1.45% on the day.
The stock trades 75.8% below its 52-week high of $45.00
and 51.2% above its 52-week low of $7.20.
Over the past year, it lost 31.8%.
Lyell Immunopharma, Inc. is part of the Health Care sector.
Key figures
- Price
- $10.88
- Day change
- -1.45%
- Volume
- 104,063
- Average volume
- 151,100
- Market cap
- 266M+
- 52-week range
- $7.20 – $45.00
- 50-day average
- $11.02
- 200-day average
- $16.87
Price action over the past year
In 252 trading sessions since October 31, 2025, LYEL closed higher on 118 days (47%).
Its best day was November 24, 2025 (+18.77%) and its worst was June 3, 2026 (-15.58%).
The stock moved 10% or more in a single session 15 times.
LYEL news
-
Nov 2, 2026:
Lyell Immunopharma To Participate in November Investor Events
-
Oct 13, 2026:
Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
-
Sep 14, 2026:
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
-
Sep 10, 2026:
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
-
Aug 6, 2026:
Lyell Immunopharma: Q2 Earnings Snapshot
-
Aug 6, 2026:
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
-
Aug 6, 2026:
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
-
Aug 6, 2026:
Here Are Thursday's Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
About Lyell Immunopharma, Inc.
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors.
Similar stocks
Find more stocks like LYEL with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.